![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H24N8O3 |
Molar mass | 460.498 g·mol−1 |
3D model ( JSmol) | |
| |
|
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriatic arthritis and Crohn's disease. [1] [2] [3] It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile. [4]
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C23H24N8O3 |
Molar mass | 460.498 g·mol−1 |
3D model ( JSmol) | |
| |
|
Zasocitinib (TAK-279, NDI-034858) is a drug which is an orally active, highly selective tyrosine kinase 2 (TYK2) inhibitor. It has been researched for various inflammatory conditions including psoriatic arthritis and Crohn's disease. [1] [2] [3] It is significantly more selective than earlier compounds over side targets such as JAK1, which is hoped to give it an improved side effect profile. [4]